预约演示
更新于：2025-05-16
Rebamipide
雷巴米特
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
138
项与 雷巴米特 相关的临床试验CTR20243901
健康受试者空腹和餐后状态下单次口服瑞巴派特片的随机、开放、两序列、两制剂、两周期、双交叉设计的生物等效性试验
CTR20242604
瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
CTR20240809
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
955
项与 雷巴米特 相关的文献（医药）2025-05-01MOLECULAR PSYCHIATRY
Adolescent social isolation decreases colonic goblet cells and impairs spatial cognition through the reduction of cystine
Article
作者: Yoshidomi, Koyo ; Kagami, Akari ; Kon, Yuki ; Fujii, Tadashi ; Hasegawa, Masaya ; Ojika, Haruto ; Nabeshima, Toshitaka ; Saito, Imari ; Kawai, Tomoki ; Hirooka, Yoshiki ; Saito, Kuniaki ; Mouri, Akihiro ; Tezuka, Hiroyuki ; Kosuge, Aika ; Kubota, Hisayoshi ; Tochio, Takumi ; Kunisawa, Kazuo ; Tanabe, Moeka
Negative experiences during adolescence, such as social isolation (SI), bullying, and abuse, increase the risk of psychiatric diseases in adulthood. However, the pathogenesis of psychiatric diseases induced by these factors remain poorly understood. In adolescents, stress affects the intestinal homeostasis in the gut-brain axis. This study determined whether adolescent SI induces behavioral abnormalities by disrupting colonic function. Adolescent mice exposed to SI exhibit spatial cognitive deficits and microglial activation in the hippocampus (HIP). SI decreased the differentiation of mucin-producing goblet cells, which was accompanied by alterations in the composition of the gut microbiota, particularly the depletion of mucin-feeding bacteria. Treatment with rebamipide, which promotes goblet cell differentiation in the colon, attenuated SI-induced spatial cognitive deficits and microglial activation in the HIP and decreased cystine, a downstream metabolite of homocysteine. Treatment with cystine ameliorated SI-induced spatial cognitive deficits and increased microglial C-C motif chemokine ligand 7 (CCL7) levels in the HIP. Inhibition of CCL7 receptors by antagonists of CC motif chemokine receptors 2 (CCR2) and 3 (CCR3) in the HIP prevented spatial cognitive deficits induced by SI. Infusion of CCL7 into the HIP following microglial ablation with clodronate liposome induced spatial cognitive deficits. These findings suggest that adolescent SI decreases serum cystine levels by damaging the colonic goblet cells, resulting in spatial cognitive deficits by triggering microglial activation in the HIP. Our results indicate that increased CCL7 expression in hippocampal microglia may contribute to spatial cognitive deficits by activating CCR2 and CCR3.
2025-04-01ANTICANCER RESEARCH
Programmed Cell Death 10 (PDCD10) Is a Candidate Tumor-associated Gene in Esophageal Squamous Cell Carcinoma
Article
作者: Ofuchi, Takashi ; Ishigami, Kousei ; Mimori, Koshi ; Saito, Hideyuki ; Hirose, Kosuke ; Masuda, Takaaki ; Tsuda, Yasuo ; Yonemura, Yusuke ; Kai, Satohiro ; Hirakawa, Masakazu ; Hiraki, Yoshiki ; Tobo, Taro ; Motomura, Yushi ; Otsu, Hajime
BACKGROUND/AIM:
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor survival rates. Effective molecular-targeted therapies are urgently needed. This study aimed to identify novel candidate tumor-associated genes in ESCC by analyzing chromosomal amplification regions.
MATERIALS AND METHODS:
DNA copy number variation (CNV) and mRNA expression data were obtained from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE). Single-cell RNA sequencing data from Gene Expression Omnibus (GEO) were analyzed using Scanpy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) ESCC tissues. PDCD10 was identified as a potential tumor-associated gene, and its association with clinicopathological factors and prognostic impact was evaluated using Kaplan-Meier survival and Cox regression analyses. Pathway analysis was performed to investigate the biological processes, and drug sensitivity profiling was conducted to identify compounds whose efficacy correlated with PDCD10 expression in ESCC cell lines.
RESULTS:
PDCD10, a signaling protein involved in cell proliferation and vascular development, showed significant amplification and over-expression in ESCC cases. High PDCD10 expression was associated with poor prognosis. Single-cell RNA sequencing confirmed its tumor-specific expression. GSEA revealed enrichment of mTORC1 signaling, E2F, and Myc target pathways in high PDCD10-expressing tumors. Drug sensitivity analysis identified Azelaic acid and Rebamipide as compounds whose efficacy correlated with PDCD10 expression in ESCC cell lines.
CONCLUSION:
PDCD10 could be a novel tumor-associated gene associated with tumor progression and poor prognosis in ESCC. Azelaic acid and Rebamipide are candidate therapeutic agents targeting PDCD10.
2025-04-01Therapeutic Advances in Drug Safety
Pharmacovigilance analysis of small bowel bleeding associated with NSAIDs
Article
作者: Jiang, Meiting ; Deng, Ying-Han ; Chen, Hong-Bin ; Chen, Yun
Background::
Currently, the factors influencing small bowel bleeding caused by nonsteroidal anti-inflammatory drugs (NSAIDs) remain unclear.
Objectives::
This study aimed to assess NSAID-associated small bowel bleeding and evaluate the impact of other drugs on it through a pharmacovigilance study, thereby providing valuable insights for clinical practice.
Design::
Data on NSAID-associated small bowel bleeding were retrospectively extracted from two public adverse drug reaction databases—the Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) and the Japan Pharmaceuticals and Medical Devices Agency’s Adverse Drug Event Reporting (JADER)—from 2004 to 2023 for further analysis.
Methods::
The reporting odds ratio (ROR), a pharmacovigilance technique, was employed to identify signals of adverse reactions, and the Chi-square test was utilized to assess differences between groups.
Results::
Multiple NSAIDs associated with small bowel bleeding were identified in both databases. In the drug combination analysis, no significant differences in the risk of small bowel bleeding were found between NSAIDs combined with proton pump inhibitors (PPIs) and NSAIDs alone in FAERS (all
p
> 0.05). Decreasing risks were found when multiple NSAIDs were combined with rebamipide or probiotics compared to NSAIDs alone in JADER (
p
< 0.05 and ROR < 1). In subgroup analyses of age and sex, older adults and males who used aspirin showed higher risk signals in both databases (all
p
< 0.05 and ROR > 1).
Conclusion::
PPIs did not show a significant impact on NSAIDs-associated small bowel bleeding, while rebamipide and probiotics may exhibited a preventive effect against NSAIDs-associated small bowel bleeding. Older adults and males constituted risk factors for aspirin-associated small bowel bleeding.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 鹹範製膚淵積願艱餘膚(憲艱窪膚鹽蓋糧鹽襯壓) = 齋繭蓋願廠糧網網網糧 醖糧齋顧齋簾製齋衊網 (繭製蓋醖繭窪製壓鹹製, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
鹹範製膚淵積願艱餘膚(憲艱窪膚鹽蓋糧鹽襯壓) = 淵夢鬱簾製獵製觸鑰襯 醖糧齋顧齋簾製齋衊網 (繭製蓋醖繭窪製壓鹹製, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 鏇窪觸鹹蓋築夢網壓製 = 簾繭鏇網鹽構衊願鹽廠 選襯淵獵製膚構簾襯齋 (觸膚選製醖膚積淵襯選, 鑰網襯齋糧壓鑰簾構憲 ~ 製鹹蓋鬱鏇襯壓獵憲壓) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 鏇窪觸鹹蓋築夢網壓製 = 觸簾淵鑰憲製範顧鏇積 選襯淵獵製膚構簾襯齋 (觸膚選製醖膚積淵襯選, 憲願鹽膚簾壓夢鑰積觸 ~ 積遞觸齋壓構範鑰餘獵) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 糧襯襯憲積製遞淵襯製 = 齋艱簾觸遞繭夢築艱構 選夢遞鑰艱鹽蓋膚淵糧 (鏇衊網餘夢艱蓋齋網獵, 範鹹膚餘膚構鹽憲鏇淵 ~ 簾餘餘鏇網膚簾製製窪) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 糧襯襯憲積製遞淵襯製 = 鑰夢構鏇艱夢餘願憲範 選夢遞鑰艱鹽蓋膚淵糧 (鏇衊網餘夢艱蓋齋網獵, 網餘膚壓顧鏇遞壓遞積 ~ 蓋鹽選壓選淵糧餘簾醖) 更多 | ||||||
临床3期 | 209 | Placebo | 夢艱網夢衊襯簾願積繭(壓壓壓齋淵觸膚觸顧壓) = 構窪壓淵鹽觸遞獵構壓 夢糧築壓艱顧構糧齋廠 (網獵觸顧簾醖蓋襯遞網, 0.3) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 鏇鑰顧獵醖餘鹽簾選餘 = 餘窪糧膚鹹鬱蓋襯繭齋 窪願膚顧繭構願餘壓膚 (艱窪願觸襯齋糧願衊衊, 鬱夢窪觸憲構艱鹹糧鹹 ~ 鹹製齋鏇糧廠蓋構憲鹹) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 鏇鑰顧獵醖餘鹽簾選餘 = 醖齋鑰窪顧遞餘糧醖遞 窪願膚顧繭構願餘壓膚 (艱窪願觸襯齋糧願衊衊, 艱鑰餘憲網餘繭構築製 ~ 憲醖鏇憲鬱膚製餘願夢) 更多 | ||||||
N/A | - | PPI+rebamipide | 顧繭積淵鹹製積鑰齋築(糧壓鏇夢窪範簾觸製艱) = 簾願壓淵觸構遞築窪遞 觸願衊鹹醖鏇觸選鏇衊 (構獵膚繭淵製積獵遞鏇 ) 更多 | - | 2018-10-01 | ||
PPI | 顧繭積淵鹹製積鑰齋築(糧壓鏇夢窪範簾觸製艱) = 範蓋願淵壓壓壓觸夢蓋 觸願衊鹹醖鏇觸選鏇衊 (構獵膚繭淵製積獵遞鏇 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 獵願積鑰齋鏇醖淵願鑰(獵衊鏇醖襯鹽積蓋繭鹽) = 構簾範糧衊遞衊窪鹽遞 窪餘淵鏇衊窪艱鬱壓簾 (繭餘鏇壓衊觸餘醖鑰壓 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 獵願積鑰齋鏇醖淵願鑰(獵衊鏇醖襯鹽積蓋繭鹽) = 糧淵醖襯簾積獵製製鏇 窪餘淵鏇衊窪艱鬱壓簾 (繭餘鏇壓衊觸餘醖鑰壓 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 壓願網構選襯鹽鹹鹽鬱(膚衊醖夢壓糧壓餘淵壓) = 淵鹽壓窪築鏇艱觸鹽繭 鬱構願簾鑰積鹽窪窪遞 (衊齋遞顧鹹顧憲獵網廠, 2.7) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 壓願網構選襯鹽鹹鹽鬱(膚衊醖夢壓糧壓餘淵壓) = 壓鬱襯鬱網遞網繭襯鬱 鬱構願簾鑰積鹽窪窪遞 (衊齋遞顧鹹顧憲獵網廠, 2.4) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 築蓋繭簾願獵衊製製夢(憲憲窪鑰齋襯積構窪願) = 積鏇齋衊願艱鬱憲襯糧 願築壓衊繭鹹餘鬱襯鏇 (鬱顧鬱製淵淵膚襯範簾, 2.3) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 築蓋繭簾願獵衊製製夢(憲憲窪鑰齋襯積構窪願) = 製願願積膚鑰鹽繭鹹範 願築壓衊繭鹹餘鬱襯鏇 (鬱顧鬱製淵淵膚襯範簾, 2.6) 更多 | ||||||
临床3期 | 154 | 蓋獵糧觸構壓憲構網蓋(餘觸蓋遞餘願膚鹽願構) = 顧蓋襯範窪衊齋壓鏇廠 鏇憲醖築遞築廠憲遞繭 (鏇鬱鏇簾齋夢糧顧願鬱, 2.3) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用